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PML nuclear bodiesa b s t r a c t
The RNF38 gene encodes a RING ﬁnger protein of unknown function. Here we demonstrate that RNF38 is
a functional ubiquitin protein ligase (E3). We show that RNF38 isoform 1 is localized to the nucleus by a
bipartite nuclear localization sequence (NLS). We conﬁrm that RNF38 is a binding partner of p53 and
demonstrate that RNF38 can ubiquitinate p53 in vitro and in vivo. Finally, we show that overexpression
of RNF38 in HEK293T cells results in relocalization of p53 to discrete foci associated with PML nuclear
bodies. These results suggest RNF38 is an E3 ubiquitin ligase that may play a role in regulating p53.
 2013 Published by Elsevier Inc.1. Introduction
The p53 tumor suppressor gene (TP53) has been termed ‘‘the
guardian of the genome’’ [1] and it is one of the most frequently
mutated genes in human cancers [2–5]. Mutations in the regula-
tors of p53, such as Arf, Mdm2 and Pirh2, are also commonly seen
in cancer cells [6–8]. Considering the extensive involvement of p53
in tumorigenesis, understanding p53 regulation is important to the
continued development of anti-cancer strategies.
In a search for new p53 interactors, Lunardi et al. employed an
afﬁnity puriﬁcation approach with Drosophila p53 in which they
identiﬁed many novel p53 binding proteins, including the little
studied protein, RING ﬁnger protein 38 (RNF38) [9]. Although hu-
man RNF38 has been previously cloned [10], its function is cur-
rently unknown.
RNF38 mRNA is widely expressed in a variety of human tissues
[10], and evolutionary conservation suggests an important cellular
function. Interestingly, RNF38 is located on an area of chromosome
9 (9p13) that is frequently deleted in multiple cancers such as gan-
glioglioma [11], lung cancer [12,13], hepatocellular carcinoma [14],
and in the 9p13-24 deletion seen in the lymphoid blast transfor-
mation of chronic myeloid leukemia [15].Many proteins containing a RING ﬁnger motif act as ubiquitin
protein ligases [16,17]. We wanted to explore the possibility that
RNF38 might have E3 activity and whether or not p53 might be a
substrate. p53 is known to be regulated by several ubiquitin pro-
tein ligases, the best studied of which is Mdm2/Hdm2. [18–20].
Other E3 ligases that can modify p53 include WWP1, Pirh2 and
Cop1 [21–23]. Here we ﬁnd that RNF38 does possess E3 ubiquitin
ligase activity and can recognize p53 as a substrate for ubiquitina-
tion. In addition, overexpression of RNF38 alters the nuclear local-
ization of p53.2. Materials and methods
2.1. Cell culture and transfections
All cell lines were obtained from the Tissue Culture Shared Re-
source at the University of Colorado Cancer Center. Human embry-
onic kidney 293 (HEK293) and HEK293T cells were maintained in
DMEM (Hyclone) supplemented with 10% fetal bovine serum and
antibiotics. H1299 cells were grown in RPMI (Hyclone) supple-
mented with 10% fetal bovine serum and antibiotics. Transfections
were performed with Lipofectamine (Invitrogen).
2.2. Constructs
cDNA for RNF38 isoform 1 was obtained by RT-PCR from
HEK293 mRNA and cloned into pcDNA 3.1(+) (Invitrogen). The
RNF38 cDNA insert and all other constructs derived by PCR were
fully sequenced. GFP fusions were made in pEGFP-C1 (Clontech).
PCR primers and cloning details are provided in the supplementary
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tained from Yusen Liu. Vector pMT 123 expressing HA-ubiquitin
was obtained from Mathias Treier.
2.3. Expression and puriﬁcation of RNF38 from baculovirus
A six histidine tag was added to the amino terminus of RNF38
by PCR and cloned into the baculovirus recombination plasmid
pVL1393. The Baculovirus Core Facility at the University of Colo-
rado Cancer Center performed the recombination into baculovirus
and growth in SF9 cells. RNF38 was puriﬁed from extracted nuclei
using immobilized Co++ (‘‘Talon’’, Clontech) afﬁnity chromatogra-
phy. Full details are provided in the supplementary data.
2.4. Antibodies
Mouse monoclonal anti-p53 (1C12) was purchased from Cell
Signaling. Rabbit anti-p53 (sc-6243), mouse monoclonal anti-p53
(sc-126), rabbit anti-RNF38 (sc-102096), rabbit anti-GFP
(sc-8334) and mouse monoclonal anti-PML (sc-966) were pur-
chased from Santa Cruz Biotechnology. A second rabbit anti-
RNF38 antibody (AP12816a) was acquired from Abgent. Mouse
anti-NR1 (#05–432) was obtained from Upstate Biotechnology.
Horseradish peroxidase (HRP) conjugated rat anti-HA antibody
(3F10) was from Roche Applied Science.
2.5. Binding studies
GST and GST-p53 fusion proteins were puriﬁed from Escherichia
coli BL21 transformed with pGEX-4T-2-(p53). Either 2 lg of puri-
ﬁed RNF38 in GST binding buffer (50 mM NaCl, 20 mM Tris pH
7.5, 1 mM MgCl2, 1 mM DTT, 0.1% Thesit and 1.0 mg/mL BSA) or
850 lg of 293T whole cell extract in lysis buffer (50 mM NaCl,
20 mM Tris pH 7.5, 1 mMMgCl2, 1.0% Trition X-100, 1 mM Na3VO4,
1 mM DTT and 1 mM PMSF plus protease inhibitors) were incu-
bated at 4 C for 30 min with equal amounts (2 lg) of GST or
GST-p53. Preblocked (5% BSA) glutathione-Sepharose beads (G.E.
Healthcare Lifesciences) were then added to the mixtures and
incubated for 2 h at 4 C with mixing. The beads were then washed
with GST wash buffer (50 mM NaCl, 20 mM Tris pH7.5, 1 mM
MgCl2, 1 mM DTT and 0.1% Thesit) and subjected to western blot
analysis.
2.6. Ubiquitination assay – in vitro
Puriﬁed RNF38 was mixed with 50 lg/ml E1, E2 and 0.5 mg/ml
HA-ubiquitin in ubiquitin buffer (50 mM KCl, 20 mMHEPES pH 7.4,
5 mM MgCl2, 1 mM DTT and 1 mM ATP) and incubated for 30 min
at 30 C with mixing at 600 rpm. The reaction products were ana-
lyzed by western blot with anti-RNF38 (sc-102096) and anti-HA
antibodies.
For in vitro p53 ubiquitination reactions, p53 was immunopre-
cipitated from HEK293T cells lysed in RIPA+ buffer (150 mM NaCl,
20 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 1.0% NP-40, 0.1% SDS,
0.5% sodium deoxycholate, 50 mM NaF, 1 mM Na3VO4, 1 mM DTT,
1 mM PMSF plus protease inhibitors). Mouse anti-p53 (1C12) or
mouse anti-NR1 control (0.75 lg) was added to 500 lg of pre-
cleared whole cell lysate and incubated overnight. Antibody
complexes were then bound to preblocked (5% BSA) protein
G-agarose (Sigma–Aldrich P-4691) for two hours followed by
extensive washing: twice with RIPA+, twice with SNNTE (0.5 M
NaCl, 50 mM Tris pH 7.5, 5 mM EDTA, 5% sucrose, 1% NP-40), twice
with 200 mM glycine pH 2.5, and twice with ubiquitin buffer. The
washed beads were then used in in vitro ubiquitination reactions
with or without puriﬁed RNF38 as described above. Following
the ubiquitination reactions, the beads were washed twice withRIPA+ and then analyzed by western blot with anti-p53 and anti-
HA antibodies.
2.7. Ubiquitination assay – in vivo
HEK293T cells were transfected with pMT 123 (HA-ubiquitin)
plus pEBG or pEBG-RNF38. 24 h post-transfection cells were pas-
saged and allowed to grow for 48 h. At 72 h post-transfection the
cells were incubated for 4 h in 25 lMMG132 (Sigma–Aldrich) then
collected in lysis buffer (100 mM NaCl, 20 mM Tris pH 7.5, 5 mM
EDTA, 10% glycerol, 1% NP-40, 1 mM DTT, 50 mM NaF, 1 mM
Na3VO4, 1 mM PMSF, 10 mMNEM plus protease inhibitors). Immu-
noprecipitation of p53 was performed using 1 lg of mouse
anti-p53 (sc-126) antibody to 1.5 mg of precleared whole cell ex-
tract followed by binding to preblocked protein G-agarose. Bound
complexes were washed with lysis buffer then analyzed by
western blot with rat anti-HA antibody.
2.8. Immunoﬂuorescence
Cultured cells were seeded on glass coverslips, transfected and
24 h later ﬁxed with 4% para-formaldehyde in PBS. Cells were per-
meabilized with cold methanol, rinsed with PBS, and blocked with
2% nonfat milk, 0.1% Tween-20 in PBS. Primary antibody rabbit
anti-p53 (sc-6243) was used at 2 lg/ml in 1% BSA, 0.5% Triton
X-100 in PBS and incubated for 1 h at room temperature. Primary
antibody rabbit anti-RNF38 (AP12816a) was used at 5 lg/ml and
anti-PML (sc-966) was used at 4 lg/ml incubated overnight at
4 C. Cells were washed with 0.05% Tween-20 in PBS and incubated
with the appropriate ﬂuorescent secondary (Alexa Fluor 568 goat
anti-rabbit or Alexa Fluor 488 goat anti-mouse, Invitrogen) at
2 lg/ml for 1 h. Nuclei were counterstained with 0.2 lg/ml Hoe-
chst 33258 (Kodak). Coverslips were mounted in gelvatol and
examined with a Nikon Eclipse Ti-S microscope ﬁtted with the
appropriate ﬂuorescence ﬁlters, DS-Qi1 camera and NIS-Elements
imaging software.3. Results
3.1. RNF38 is a nuclear protein
In their study identifying p53-interacting proteins in Drosophila,
Lunardi et al. also examined the intracellular localization of 41
mammalian orthologs, including RNF38 [9]. Immunoﬂuorescence
of epitope-tagged RNF38 overexpressed in U2OS cells revealed
diffuse nuclear staining. However, the data presented was a
supplementary ﬁgure containing an image of a single cell
with no mention of which RNF38 isoform was used or if any
other staining patterns were observed. As a ﬁrst step toward
understanding RNF38 function, we sought to conﬁrm and expand
this result.
We ﬁrst examined RNF38 in HEK293T cells. Endogenous RNF38
was detectable by immunoﬂuorescence with only one of two com-
mercially available anti-RNF38 antibodies (AP12816a) under the
conditions employed. Similar to the results of Lunardi et al., we
ﬁnd endogenous RNF38 is also localized to the nucleus in HEK293T
cells (Fig. 1A). RNF38 is predicted to have three isoforms. Isoform 1
is the largest, containing 515 amino acids, whereas isoform 2 lacks
amino acids 5–54, and isoform 3 lacks amino acids 1–84. According
to the manufacturer, the AP12816a antibody was raised against
amino acids 47–77 of RNF38, a region present in isoform 1 but par-
tially or entirely lacking in the other isoforms. We chose to focus
on isoform 1, henceforth referred to as simply ‘‘RNF38’’.
The endogenous RNF38 signal was fairly weak, so to further
investigate RNF38 nuclear localization, we constructed a
Fig. 1. RNF38 is a nuclear protein with a bipartite nuclear localization signal. (A) Endogenous RNF38 is located in the nucleus. HEK293T cells were stained with anti-RNF38
antibody, nuclei were counterstained with Hoechst 33258 and cells examined by ﬂuorescence microscopy. (B) RNF38 contains two potential nuclear localization signals. In
silico searches identiﬁed amino acids 57–71 (red) and 115–131 (blue) as possible nuclear localization signals. The RING ﬁnger domain is also indicated (463–506). (C) GFP-
RNF38 fusion constructs used to test candidate nuclear localization signals. (D) Amino acid sequence 57–131 is sufﬁcient for nuclear localization. At 24 h post-transfection
with the constructs shown in (C), HEK293T cells were ﬁxed and treated as in (A). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
J.E. Sheren, C.K. Kassenbrock / Biochemical and Biophysical Research Communications 440 (2013) 473–478 475GFP-tagged RNF38 expression vector. As shown in Fig. 1, transient
expression (Fig. 1D, second row) resulted in nuclear localization of
GFP-RNF38. Note also that the stronger signal from overexpressed
GFP-RNF38 allows more detail to be observed, and the protein ap-
pears to be excluded from nucleoli.Fig. 2. RNF38 is capable of autoubiquitination in vitro. Reactions contained
recombinant RNF38, E1, HA-ubiquitin, and either UbcH2, UbcH5b or UbcH7 with
or without 1 mM ATP. Puriﬁed GST was used as a control. Reactions were analyzed
by immunoblot with anti-RNF38 (sc-102096) and anti-HA antibodies.3.2. Identiﬁcation of nuclear localization signals
To identify the motif(s) responsible for RNF38 nuclear localiza-
tion we analyzed its amino acid sequence with several nuclear
localization signal (NLS) prediction programs. cNLS Mapper [24]
identiﬁed amino acids 57–71 as a possible NLS, and amino acids
115–131 were identiﬁed as a possible NLS by NLStradamus [25].
We then created a series of GFP fusions to examine the role these
sequences might play in RNF38 localization (Fig. 1C).
Transient expression of GFP in HEK293T cells results in a uni-
form staining pattern throughout the nucleus and cytoplasm
(Fig. 1D). In contrast, the GFP-RNF38 fusion protein appears re-
stricted to the nucleus. GFP fusion to either amino acids 57–71
or 115–131 is insufﬁcient to confer complete nuclear localization,
though a larger GFP fusion to amino acids 57–131 is completely
localized to the nucleus. This region contains both of the basic res-
idue-rich sequences identiﬁed as putative NLSs and thus appears to
function as a bipartite NLS. Deletion of this region results in loss of
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protein localized in both cytoplasm and nucleus.3.3. RNF38 is an E3 ubiquitin ligase
In addition to ubiquitination of their target proteins, many E3
ubiquitin ligases undergo autoubiquitination in vitro [16,17].
Fig. 2 shows in vitro ubiquitination assays using His-tagged
RNF38 puriﬁed from baculovirus infected SF9 cells. RNF38 clearly
undergoes robust autoubiquitination and shows speciﬁcity in
interacting with E2s. Of the three E2 proteins tested (UbcH2,
UbcH5b and UbcH7), only UbcH5b supported RNF38 autoubiquiti-
nation. These ﬁndings demonstrate RNF38 is an active ubiquitin
protein ligase (E3).Fig. 3. RNF38 binds and ubiquitinates p53. (A) RNF38 binds to p53 in vitro. Binding inte
GST-p53 followed by binding to glutathione-Sepharose. Bound proteins were analyzed b
p53. 293T cell lysate was incubated with puriﬁed GST or GST-p53. Complexes were isola
comparison. (C) p53 is ubiquitinated by puriﬁed RNF38 in vitro. p53 was immunoprecip
Isoloated immune complexes were added to in vitro ubiquitination reactions with recom
products were analyzed by immunoblot with antibodies to p53 and HA (ubiquitin).
transfected with pMT 123 (HA-ubiquitin) plus either the pEBG expression vector or pEBG
and p53 recovered by immunoprecipitation. Precipitated proteins were analyzed by we3.4. The RING domain limits RNF38 overexpression
We found RNF38 to be resistant to overexpression by transfec-
tion despite using a variety of expression plasmids and cell lines
(including MDA-MB-231, H1299 and HEK293, data not shown).
Since an active RING domain might limit expression through auto-
ubiquitination or down-regulation of some other cellular compo-
nent, we removed the C-terminal RING domain from RNF38
(RNF38 DRING) to explore the issue.
Truncation of the RING domain greatly increased RNF38
expression (Fig. S1A). In two cell types (HEK293T and H1299),
transfection with GFP alone or GFP-RNF38DRING yielded many
GFP-positive cells, whereas with full-length GFP-RNF38, only rare
GFP-positive cells were observed. Western blot analysis of these
cells conﬁrmed the results (Fig. S1B).ractions were tested using recombinant RNF38 incubated either alone, with GST, or
y immunoblot with anti-RNF38 antibody (sc-102096). (B) Endogenous RNF38 binds
ted and analyzed as in (A). Lane one (Lysate) contains 3.5% of the cell lysate used for
itated from 293T cell lysate using mouse anti-p53 or a control antibody (anti-NR1).
binant HA-ubiquitin, E1, UbcH5b and with or without RNF38, as indicated. Reaction
(D) Overexpression of RNF38 increases p53 ubiquitination. HEK293T cells were
-RNF38. 72 h post-transfection, cells were treated with 25 lMMG132 for 4 h, lysed,
stern blot with anti-HA antibody.
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detectable on western blots using derivatives of the vector pEBG
in HEK293T cells (Fig. S1C). The pEBG plasmid contains an SV40
origin of replication, allowing ampliﬁcation of the plasmid in
HEK293T cells which express SV40 large T antigen. Treatment of
cells with the proteasome inhibitor MG132 did not increase
RNF38 expression, nor was a prominent ladder of ubiquitinated
RNF38 species observed, suggesting that autoubiquitination may
not be the mechanism limiting overexpression of full-length
RNF38 (Fig. S1C). Additional experiments will be required to iden-
tify the mechanism(s) regulating RNF38 expression.3.5. RNF38 is a p53 binding protein
We have examined the p53-RNF38 binding interaction ﬁrst re-
ported by Lunardi et al. using a different afﬁnity puriﬁcation tech-
nique employing a fusion protein between human p53 and
glutathione S-transferase (GST). Puriﬁed RNF38 binds speciﬁcally
to GST-p53 but not GST alone (Fig. 3A, upper panel). Similarly,
endogenous RNF38 in lysates of HEK293T cells speciﬁcally binds
GST-p53 but not GST alone (Fig. 3B).3.6. RNF38 ubiquitinates p53 in vitro and in vivo
To test whether p53 is a substrate for ubiquitination by RNF38,
endogenous p53 was immunoprecipitated from HEK293T lysate
and added to in vitro ubiquitination reactions. Control immunopre-
cipitates using an unrelated antibody (anti-NR1) were treated
similarly. We found that p53 was ubiquitinated in an RNF38-
dependent manner under these conditions (Fig. 3C).
Next, we asked whether we could detect RNF38-dependent
ubiquitination of p53 in cells. HEK293T cells were transfected with
an expression vector for HA-tagged ubiquitin and either GST or
GST-RNF38. p53 was recovered by immunoprecipitation and ana-
lyzed by immunoblotting for HA-ubiquitin (Fig. 3D). GST-RNF38
clearly increased p53 ubiquitination in vivo, as evidenced by the
ladder of higher molecular weight species reacting with HA (ubiq-
uitin) antibody. We note that the p53 complexes isolated from cells
appear more extensively modiﬁed than those produced in vitro,Fig. 4. RNF38 overexpression alters p53 localization. (A) HEK293T cells were transfected
stained for p53. A representative image of p53 punctate structure is shown. (B) The p53
cells. Approximately 200 cells each were counted. (C) RNF38 overexpression induces p5
RNF38. 24 h post-transfection cells were ﬁxed and stained for p53 (sc-6243) and PML.suggesting there may be additional factors or conditions involved
in p53 ubiquitination in cells.
Investigation of possible effects of RNF38 on p53 turnover has
been hindered by the resistance of RNF38 to overexpression. As
mentioned earlier, detection of biochemical levels of exogenous
RNF38 has only been achieved in HEK293T cells, in which SV40
large T antigen prevents normal p53 turnover [26]. Experiments
in other systems, including H1299 cells (which lack p53 expres-
sion), have been inconclusive due to insufﬁcient/undetectable
RNF38 expression.
3.7. Overexpression of RNF38 alters p53 localization
Since biochemical analysis of possible RNF38 effects on p53
turnover has been uninformative due to the technical issues
described above, we turned to ﬂuorescence microscopy to allow
visualization of any effects on intracellular localization of p53.
HEK293T cells were transfected with GFP-RNF38 or GFP alone,
then ﬁxed and stained for p53. In untransfected and GFP-transfec-
ted HEK293T cells, p53 is distributed diffusely throughout the
nucleus with a small minority of cells (13%) showing punctate
staining (Fig. 4). In cells transfected with GFP-RNF38, p53 redistrib-
uted to large punctate structures in the nucleus in the majority of
GFP-RNF38 positive cells (69%).
Since p53 has been previously identiﬁed in PML (promyelocytic
leukemia-associated protein) nuclear bodies [27,28], we analyzed
the localization of PML and p53 in RNF38 transfected cells. A typ-
ical cell with a punctate p53 phenotype is shown in Fig. 4C. In these
cells many, though not all, p53 foci associate directly adjacent to
PML nuclear bodies. The number of p53 and PML foci vary from cell
to cell, and while many p53 foci colocalize with PML foci, a few of
each type do not. These data suggest that overexpression of RNF38
can change the distribution of p53 within the nucleus from diffuse
to punctate, and many of these foci are associated with PML nucle-
ar bodies.
4. Discussion
This study has begun the functional characterization of the evo-
lutionarily conserved protein, RNF38. We have shown that RNF38with pEBG-GFP or pEBG-GFP-RNF38. At 24 h post-transfection, cells were ﬁxed and
phenotype was quantiﬁed as punctate or non-punctate in GFP(RNF38) expressing
3 association with PML nuclear bodies. HEK293T cells were transfected with pEBG-
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identiﬁed a bipartite NLS capable of mediating this localization. We
have expressed and puriﬁed RNF38 from baculovirus-infected SF9
cells and found that puriﬁed RNF38 protein is an active ubiquitin
protein ligase that exhibits speciﬁcity with the E2 protein with
which it interacts. We have conﬁrmed Lunardi et al.’s ﬁndings that
RNF38 is a p53-binding protein, shown that RNF38 can ubiquiti-
nate p53 in vitro, and demonstrated that overexpression of
RNF38 increases p53 ubiquitination in vivo.
Although our efforts to elucidate the dynamics of the
p53-RNF38 interaction biochemically were hindered by limited
RNF38 overexpression, ﬂuorescence microscopy revealed that
overexpression of RNF38 in HEK293T cells alters the intracellular
distribution of p53 from a diffuse nuclear pattern to punctate foci,
many of which are associated with PML nuclear bodies. Association
of p53 with PML nuclear bodies has been previously described in a
number of instances [27–30], and it has been suggested that PML
nuclear bodies may be sites of functional regulation of p53 [31].
In this regard, our data indicating altered p53 localization upon
RNF38 overexpression are intriguing. While insufﬁcient to illumi-
nate the exact functional interplay between these two proteins,
these results do provide additional evidence for a regulatory
relationship between RNF38 and p53. Taken together with our
other ﬁndings, a case can be made that RNF38 may be a biologi-
cally signiﬁcant regulator of p53. It remains to future studies to
elaborate the full functional details of such regulation.
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